Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

TitleTreatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
Publication TypeJournal Article
Year of Publication2019
AuthorsChiotos K, Hayes M, Gerber JS, Tamma PD
JournalJ Pediatric Infect Dis Soc
Date Published2019 Dec 21
ISSN2048-7207
Abstract

Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes. Optimal treatment strategies for CRE infections continue to evolve. A lack of pediatric-specific comparative effectiveness data, uncertain pediatric dosing regimens for several agents, and a relative lack of new antibiotics with pediatric indications approved by the US Food and Drug Administration (FDA) collectively present unique challenges for children. In this review, we provide a framework for antibiotic treatment of CRE infections in children, highlighting relevant microbiologic considerations and summarizing available data related to the evaluation of FDA-approved antibiotics (as of September 2019) with CRE activity, including carbapenems, ceftazidime-avibactam, meropenem-vaborbactam, imipenem/cilastatin-relebactam, polymyxins, tigecycline, eravacycline, and plazomicin.

DOI10.1093/jpids/piz085
Alternate JournalJ Pediatric Infect Dis Soc
PubMed ID31872226